Current new challenges in the management of ulcerative colitis

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Ulcerative colitis (UC) is a chronic inflammatory condition of the gastrointestinal tract. Although the cause of UC is postulated to be multifactorial in nature, including genetic predisposition, epithelial barrier defects, dysregulation of immune responses, and environmental factors, the specific pathogenesis of UC is still incompletely understood. In the treatment of UC so far, a method of suppressing immunity and treating it has been mainstream. Immunosuppressant drugs, including thiopurines (azathioprine or 6-mercaptopurine), anti-tumor necrosis factor-α (anti-TNF-α) antibody (infliximab and adalimumab), and calcineurin inhibitor, can be used in treat patients with corticosteroid-dependent and/or corticosteroid-refractory moderateto-severe UC. Recently, in addition to such a conventional therapeutic agent, golimumab, which is the first transgenic human monoclonal anti-TNF-α antibody to be fabricated, anti α-4/β-7 integrin antibody, and Janus kinase inhibitor have been reported to novel immunosuppressant therapy. Furthermore, other treatments with unique mechanisms different from immunosuppression, have also been suggested, including fecal microbiota transplantation and Indigo naturalis, which is a Chinese herbal medicine. We compared the features and efficacy of these new treatments. In this issue, the features and treatment options for these new treatments is reviewed.

Original languageEnglish
Pages (from-to)36-44
Number of pages9
JournalIntestinal Research
Volume17
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Ulcerative Colitis
Immunosuppressive Agents
Antibodies
Adrenal Cortex Hormones
Therapeutics
Tumor Necrosis Factor-alpha
Indigo Carmine
Janus Kinases
6-Mercaptopurine
Herbal Medicine
Azathioprine
Genetic Predisposition to Disease
Integrins
Immunosuppression
Gastrointestinal Tract
Immunity
Pharmaceutical Preparations

Keywords

  • Colitis, ulcerative
  • Fecal microbiota transplantation
  • Indigo naturalis
  • Tofacitinib
  • Vedolizumab

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Current new challenges in the management of ulcerative colitis. / Fukuda, Tomohiro; Naganuma, Makoto; Kanai, Takanori.

In: Intestinal Research, Vol. 17, No. 1, 01.01.2019, p. 36-44.

Research output: Contribution to journalReview article

@article{a1371d1d3c4446609c983fda9692bf14,
title = "Current new challenges in the management of ulcerative colitis",
abstract = "Ulcerative colitis (UC) is a chronic inflammatory condition of the gastrointestinal tract. Although the cause of UC is postulated to be multifactorial in nature, including genetic predisposition, epithelial barrier defects, dysregulation of immune responses, and environmental factors, the specific pathogenesis of UC is still incompletely understood. In the treatment of UC so far, a method of suppressing immunity and treating it has been mainstream. Immunosuppressant drugs, including thiopurines (azathioprine or 6-mercaptopurine), anti-tumor necrosis factor-α (anti-TNF-α) antibody (infliximab and adalimumab), and calcineurin inhibitor, can be used in treat patients with corticosteroid-dependent and/or corticosteroid-refractory moderateto-severe UC. Recently, in addition to such a conventional therapeutic agent, golimumab, which is the first transgenic human monoclonal anti-TNF-α antibody to be fabricated, anti α-4/β-7 integrin antibody, and Janus kinase inhibitor have been reported to novel immunosuppressant therapy. Furthermore, other treatments with unique mechanisms different from immunosuppression, have also been suggested, including fecal microbiota transplantation and Indigo naturalis, which is a Chinese herbal medicine. We compared the features and efficacy of these new treatments. In this issue, the features and treatment options for these new treatments is reviewed.",
keywords = "Colitis, ulcerative, Fecal microbiota transplantation, Indigo naturalis, Tofacitinib, Vedolizumab",
author = "Tomohiro Fukuda and Makoto Naganuma and Takanori Kanai",
year = "2019",
month = "1",
day = "1",
doi = "10.5217/ir.2018.00126",
language = "English",
volume = "17",
pages = "36--44",
journal = "Intestinal Research",
issn = "1598-9100",
publisher = "Korean Association for the Study of Intestinal Diseases",
number = "1",

}

TY - JOUR

T1 - Current new challenges in the management of ulcerative colitis

AU - Fukuda, Tomohiro

AU - Naganuma, Makoto

AU - Kanai, Takanori

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Ulcerative colitis (UC) is a chronic inflammatory condition of the gastrointestinal tract. Although the cause of UC is postulated to be multifactorial in nature, including genetic predisposition, epithelial barrier defects, dysregulation of immune responses, and environmental factors, the specific pathogenesis of UC is still incompletely understood. In the treatment of UC so far, a method of suppressing immunity and treating it has been mainstream. Immunosuppressant drugs, including thiopurines (azathioprine or 6-mercaptopurine), anti-tumor necrosis factor-α (anti-TNF-α) antibody (infliximab and adalimumab), and calcineurin inhibitor, can be used in treat patients with corticosteroid-dependent and/or corticosteroid-refractory moderateto-severe UC. Recently, in addition to such a conventional therapeutic agent, golimumab, which is the first transgenic human monoclonal anti-TNF-α antibody to be fabricated, anti α-4/β-7 integrin antibody, and Janus kinase inhibitor have been reported to novel immunosuppressant therapy. Furthermore, other treatments with unique mechanisms different from immunosuppression, have also been suggested, including fecal microbiota transplantation and Indigo naturalis, which is a Chinese herbal medicine. We compared the features and efficacy of these new treatments. In this issue, the features and treatment options for these new treatments is reviewed.

AB - Ulcerative colitis (UC) is a chronic inflammatory condition of the gastrointestinal tract. Although the cause of UC is postulated to be multifactorial in nature, including genetic predisposition, epithelial barrier defects, dysregulation of immune responses, and environmental factors, the specific pathogenesis of UC is still incompletely understood. In the treatment of UC so far, a method of suppressing immunity and treating it has been mainstream. Immunosuppressant drugs, including thiopurines (azathioprine or 6-mercaptopurine), anti-tumor necrosis factor-α (anti-TNF-α) antibody (infliximab and adalimumab), and calcineurin inhibitor, can be used in treat patients with corticosteroid-dependent and/or corticosteroid-refractory moderateto-severe UC. Recently, in addition to such a conventional therapeutic agent, golimumab, which is the first transgenic human monoclonal anti-TNF-α antibody to be fabricated, anti α-4/β-7 integrin antibody, and Janus kinase inhibitor have been reported to novel immunosuppressant therapy. Furthermore, other treatments with unique mechanisms different from immunosuppression, have also been suggested, including fecal microbiota transplantation and Indigo naturalis, which is a Chinese herbal medicine. We compared the features and efficacy of these new treatments. In this issue, the features and treatment options for these new treatments is reviewed.

KW - Colitis, ulcerative

KW - Fecal microbiota transplantation

KW - Indigo naturalis

KW - Tofacitinib

KW - Vedolizumab

UR - http://www.scopus.com/inward/record.url?scp=85062236774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062236774&partnerID=8YFLogxK

U2 - 10.5217/ir.2018.00126

DO - 10.5217/ir.2018.00126

M3 - Review article

AN - SCOPUS:85062236774

VL - 17

SP - 36

EP - 44

JO - Intestinal Research

JF - Intestinal Research

SN - 1598-9100

IS - 1

ER -